Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
Healthcare
$12.44 +1.78%
+$0.31 today
- Market cap
- $1.16B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
52W Low $16.92High $48.45
Volume 0.00M
Average 0.01M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$1.17B
FY 2025 · Annual
Investing Cash Flow
-$1.00B
FY 2025 · Annual
Financing Cash Flow
$2.54B
FY 2025 · Annual
+707.0% YoYCash Flow Statement
CNY
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.24B) |
| Depreciation & Amortization | 28.33M | 62.92M | 93.2M | 93.17M | 86.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.97M | 22.11M | 31.5M | 20.92M | 20.87M |
| Change in Working Capital | (74.91M) | 104.41M | (9.15M) | 110.97M | (143.5M) |
| Accounts Receivables | (53.97M) | (388K) | (91.54M) | 62.75M | (169.8M) |
| Inventory | (3.93M) | (5.52M) | (6.72M) | 9.57M | (26.2M) |
| Accounts Payables | 0 | 24.7M | (23.11M) | 19.52M | 14.77M |
| Other Working Capital | (17.01M) | 85.62M | 112.22M | 19.13M | 37.72M |
| Other Non-Cash Items | 227.18M | 43.82M | 91.23M | 58.84M | 98.07M |
| Operating Cash Flow | (604.68M) | (653.92M) | (726.08M) | (111.36M) | (1.17B) |
| Capital Expenditures | (436.63M) | (236.96M) | (56.84M) | (24.29M) | (27.57M) |
| Acquisitions (Net) | (36.2M) | (20M) | (20M) | (25.52M) | (43.34M) |
| Purchases of Investments | (1.78B) | (130M) | 0 | (312.23M) | (929.14M) |
| Sales of Investments | 1.79B | 0 | 0 | 0 | 0 |
| Other Investing Activities | (879K) | (31.32M) | 88.03M | (312.23M) | 0 |
| Investing Cash Flow | (466.52M) | (384.61M) | 21.92M | (362.04M) | (1B) |
| Debt Repayment | 548.59M | 695.87M | (13.36M) | (145.34M) | 307.26M |
| Common Stock Issued | 1.3B | 0 | 470.08M | 533.94M | 2.3B |
| Common Stock Repurchased | (25.87M) | (26.78M) | (5.92M) | 0 | (9.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (41.97M) | (49.83M) | (82.05M) | (73.83M) | (63.04M) |
| Financing Cash Flow | 1.78B | 619.27M | 368.75M | 314.77M | 2.54B |
| Effect of Forex Changes | (23.28M) | 58.01M | 27.81M | 13.68M | (63.24M) |
| Net Change in Cash | 686.91M | (361.25M) | (307.59M) | (144.95M) | 302.68M |
| Free Cash Flow | (1.04B) | (890.88M) | (782.92M) | (135.65M) | (1.2B) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$1.2B
+ D&A$86.5M
+ Stock-Based Comp$20.9M
+ Deferred Tax$0
- Working Capital-$143.5M
+ Other Non-Cash$98.1M
= Operating Cash Flow-$1.2B
- Capex-$27.6M
= Free Cash Flow-$1.2B
Analysis
FY2025 free cash flow is -$1.2B. FCF conversion is 97.2% of net income. Operating cash flow was -$1.2B, with capex of -$27.6M. The largest bridge item is Working Capital at -$143.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| 6-K | 6-K filing | Oct 21, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 |
Does AAPG generate free cash flow?
Ascentage Pharma Group International (AAPG) generated -$1.20B of free cash flow in fiscal 2025.
How much operating cash flow does AAPG produce?
Operating cash flow was -$1.17B, before capital expenditures of $27.57M.
Continue the stock analysis
Jump to another research area for this company.